BTAIQ BIOXCEL THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, BIOXCEL THERAPEUTICS INC reported revenue of $182K (up 51.7% from a year earlier), net income of −$14.7M and diluted EPS of −$0.49; over the last four quarters revenue was $742K and net income −$70.9M; for the fiscal year ended December 2025 revenue was $642K, down 71.7% on the year before.
BTAIQ annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $642K, gross profit n/a, operating income −$50.5M, net income −$69.9M (margin -10887.4%), EPS −$5.73
- Fiscal year ended Dec 2024: revenue $2.27M, gross profit n/a, operating income −$67.2M, net income −$59.6M (margin -2630.1%), EPS −$23.51
- Fiscal year ended Dec 2023: revenue $1.38M, gross profit n/a, operating income −$172M, net income −$179M (margin -12974.9%), EPS −$98.33
- Fiscal year ended Dec 2022: revenue $375K, gross profit n/a, operating income −$160M, net income −$166M (margin -44201.9%), EPS −$5.92
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$107M, net income −$107M (margin n/a), EPS −$4.05
BTAIQ quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $182K (up 51.7% year over year), net income −$14.7M, EPS −$0.49
- Quarter ended Mar 31, 2026: revenue $206K (up 22.6% year over year), net income −$12.7M, EPS −$0.54
- Quarter ended Dec 31, 2025 (from the annual report): revenue $256K (down 30.1% year over year), net income −$12.5M, EPS $0.40
- Quarter ended Sep 30, 2025: revenue $98.0K (down 54.2% year over year), net income −$30.9M, EPS −$2.18
- Quarter ended Jun 30, 2025: revenue $120K (down 89.1% year over year), net income −$19.2M, EPS −$2.45
- Quarter ended Mar 31, 2025: revenue $168K (down 71.1% year over year), net income −$7.25M, EPS −$1.50
- Quarter ended Dec 31, 2024 (from the annual report): revenue $366K (down 2.7% year over year), net income −$10.9M, EPS −$1.17
- Quarter ended Sep 30, 2024: revenue $214K (down 37.2% year over year), net income −$13.7M, EPS −$5.15
- Quarter ended Jun 30, 2024: revenue $1.10M (up 141.6% year over year), net income −$8.30M, EPS −$3.30
- Quarter ended Mar 31, 2024: revenue $582K (up 182.5% year over year), net income −$26.8M, EPS −$13.89
- Quarter ended Dec 31, 2023 (from the annual report): revenue $376K, net income −$22.3M, EPS −$92.94
- Quarter ended Sep 30, 2023: revenue $341K (up 148.9% year over year), net income −$50.5M, EPS −$1.72
- Quarter ended Jun 30, 2023: revenue $457K, net income −$53.5M, EPS −$1.83
- Quarter ended Mar 31, 2023: revenue $206K, net income −$52.8M, EPS −$1.84
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$54.8M, EPS −$1.96
- Quarter ended Sep 30, 2022: revenue $137K, net income −$41.8M, EPS −$1.49
- Quarter ended Jun 30, 2022: revenue n/a, net income −$37.7M, EPS −$1.35
- Quarter ended Mar 31, 2022: revenue n/a, net income −$31.5M, EPS −$1.12
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$26.1M, EPS −$0.90
- Quarter ended Sep 30, 2021: revenue n/a, net income −$26.8M, EPS −$0.96
BTAIQ cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$57.6M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$72.0M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$155M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$135M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$82.2M, share buybacks n/a
BTAIQ balance sheet
- Jun 30, 2026: cash $12.8M, total assets $28.8M, total liabilities $144M, shareholders' equity −$115M, long-term debt $0
- Mar 31, 2026: cash $17.2M, total assets $34.0M, total liabilities $140M, shareholders' equity −$106M, long-term debt $77.9M
- Dec 31, 2025: cash $28.4M, total assets $44.9M, total liabilities $140M, shareholders' equity −$95.5M, long-term debt $84.7M
- Sep 30, 2025: cash $36.2M, total assets $44.8M, total liabilities $134M, shareholders' equity −$88.9M, long-term debt $92.3M
- Jun 30, 2025: cash $17.4M, total assets $25.8M, total liabilities $133M, shareholders' equity −$108M, long-term debt $97.5M
- Mar 31, 2025: cash $31.0M, total assets $38.6M, total liabilities $129M, shareholders' equity −$90.2M, long-term debt $99.9M
- Dec 31, 2024: cash $29.9M, total assets $38.3M, total liabilities $131M, shareholders' equity −$93.1M, long-term debt $103M
- Sep 30, 2024: cash $40.4M, total assets $48.9M, total liabilities $135M, shareholders' equity −$85.6M, long-term debt $104M
What is BTAIQ's revenue?
BIOXCEL THERAPEUTICS INC reported $742K of revenue over its last four quarters, through June 30, 2026.
Is BTAIQ profitable?
No. BIOXCEL THERAPEUTICS INC lost $70.9M over the last four quarters.
What is BTAIQ's EPS?
Diluted earnings per share over the last four quarters were −$2.81; −$0.49 in the latest quarter.